Rising Hearing Loss in Africa by 2030: Urgent Measures Needed

By Crystal Lubbe

October 17, 2024

hearing loss Africa 2030

The article from the World Health Organization (WHO) Regional Office for Africa, titled “Burden of hearing loss in Africa could rise to 54 million by 2030: WHO report,” presents a comprehensive analysis of the “burden of hearing loss in Africa” and its future projections.

Current Hearing loss Prevalence and Projections for 2030

Currently, 40 million people in Africa manage hearing loss, and this number will likely grow to 54 million by 2030. Without action, the burden of hearing loss in Africa will rise to 97 million by 2050.

Economic and Social Impact of hearing loss in Africa

The economic and social impact of hearing loss is significant, costing the continent around $27 billion annually. This issue profoundly affects human lives, delaying language development in children, leading to poor educational outcomes, and limiting career prospects. Furthermore, adults face increased risks of isolation, loneliness, depression, and dementia.

Factors Driving the Surge in Hearing Loss

Hearing loss in Africa is exacerbated by several factors, including a severe shortage of ear and hearing care (EHC) specialists, with over 56% of African countries having only one ear, nose, and throat (ENT) specialist per million people, compared to approximately 50 per million in Europe. This workforce is also unevenly distributed, concentrated mainly in urban areas, leaving rural populations underserved. Furthermore, only about 10% of the 33 million Africans in need of hearing aids have access, largely due to high costs and financial barriers.

Preventable Causes

A significant portion of hearing loss is preventable. Up to 75% of hearing loss in children from low- and middle-income countries results from preventable causes such as infections, common ear diseases, and birth complications. Nonetheless, many countries fail to conduct routine hearing screenings for newborns.

Integration and Policy Gaps

EHC services are often not included in priority health programs like school health, occupational health, or healthy aging initiatives. Many nations lack national policies to strengthen EHC delivery, and those with plans often see low implementation levels. Alarmingly, 35% of countries do not provide a budget for EHC activities, shifting the financial burden onto patients.

Recommendations

The report urges several critical actions:

  • Nations must advocate for policies focused on EHC and related activities.
  • Countries should integrate EHC into existing health programs to maximize resource use.
  • Authorities need to pursue public-private partnerships to strengthen EHC services.
  • Governments must allocate dedicated funding to equip facilities, provide essential products and technologies, and boost health workforce capacity and EHC research.

Overall, the report emphasizes the urgent necessity for comprehensive and integrated strategies to tackle the growing burden of hearing loss in Africa effectively.

Reference url

Recent Posts

pharmaceutical access initiative
Pharmaceutical Access Initiative Promotes Unified Health Systems in Europe

By João L. Carapinha

June 12, 2026

The pharmaceutical access initiative led by the Beneluxa countries urges EU and EEA Member States to pursue closer coordination on medicine affordability and supply security. By combining forces, nations can protect universal health systems that treat healthcare as a social right while still enco...
health economic security
Health Economic Security as a Pillar for Growth in Central and Eastern Europe

By HEOR Staff Writer

June 12, 2026

Central and Eastern European nations face intensifying demographic pressures, including rapid population aging, shrinking workforces, and heightened security risks that endanger long-term prosperity. In a recent EFPIA statement, health economic security is seen as essential, as targeted healthcar...
gene therapy reimbursement
Gene Therapy Reimbursement Strategies for Vision Restoration

By HEOR Staff Writer

June 12, 2026

Gene therapy reimbursement in the Netherlands has demonstrated clear clinical value since the 2021 conditional access agreement for voretigene neparvovec (Luxturna®). Five years of structured real-world use confirmed that carefully designed protocols successfully selected appropriate patients wit...